Menu

Pharma News

MD002152

Merck to create spin off for women’s health and biosimilars

Home/Pharma News | Posted 21/02/2020

US pharma giant Merck is to create a spin-off company for its women’s health, biosimilars and legacy products, allowing the main company to focus on blockbuster cancer drug Keytruda (pembrolizumab).

19646665_l

US health insurers partner with generics maker Civica

Home/Pharma News | Posted 14/02/2020

The Blue Cross Blue Shield Association (BCBSA), a federation of health insurers in the US, has formed a partnership with generics manufacturer Civica Rx to reduce the costs of generic drugs.

Law V13C29

Coherus signs licensing deal for bevacizumab biosimilar in the US

Home/Pharma News | Posted 07/02/2020

US-based Coherus BioSciences (Coherus) announced on 13 January 2020 that it had entered into a licensing agreement with Chinese biopharmaceutical firm Innovent Biologics (Innovent) for its bevacizumab product, IBI305.

2019 V20A31

Top 10 most read GaBI Online articles in 2019

Home/Pharma News | Posted 31/01/2020

It has once again been a busy year for biosimilars. One of the most important milestones for biosimilars in 2019 was the World Health Organization (WHO) pilot programme to prequalify rituximab and trastuzumab biosimilars. Other subjects of interest for biosimilars were US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals, naming and regulation of biosimilars, as well as biosimilar guidance, uptake and switching.

16704526_l

Mundipharma and Samsung Bioepis partner for biosimilars in Hong Kong and Taiwan

Home/Pharma News | Posted 24/01/2020

Mundipharma announced on 13 January 2020 that it had entered into a partnership with Korea-based Samsung Bioepis (Samsung and Biogen’s joint venture) to commercialize four biosimilar candidates from Samsung Bioepis in Hong Kong and Taiwan.

Age-related macular degeneration V15b19

Japanese firms to collaborate on Eylea biosimilar

Home/Pharma News | Posted 10/01/2020

Japanese pharmaceutical firms Gene Techno Science and Kishi Kasei announced on 2 December 2019 an agreement for the joint development of an aflibercept biosimilar, a treatment for macular degeneration to rival the reference drug Eylea.

Samsung Bioepis Engineers V16K25LB R

Samsung Bioepis expands biosimilars agreement with Biogen

Home/Pharma News | Posted 06/12/2019

Korean biosimilars giant Samsung Bioepis has extended its commercialization agreement with Biogen to include biosimilars to two ophthalmology drugs, Lucentis (ranibizumab) and Eylea (aflibercept). The agreement also allows Biogen to commercialize Samsung’s blockbuster anti-inflammatories in Europe for an additional five years.

Contract Tender V13H30

Alvotech signs agreements with Stada and Yas Holding

Home/Pharma News | Posted 29/11/2019

Alvotech has entered into a strategic biosimilars collaboration with German company Stada. The company has also announced a significant investment from Abu Dhabi-based company Yas Holding for the exclusive supply of biosimilars in the Middle East and North Africa.

62 MD001919

Lupin to sell its Japanese arm and Sandoz to acquire Aspen’s Japanese business

Home/Pharma News | Posted 22/11/2019

On 11 November 2019, India-based Lupin announced that it has agreed to sell its entire stake in its Japanese subsidiary Kyowa Pharmaceutical Industry Co to Japan-based private equity firm Unison Capital for an enterprise value of Yen 57.36 billion.

Bone cells V17C04

Alvogen gains exclusive rights to market parathyroid biosimilar in three countries

Home/Pharma News | Posted 15/11/2019

American pharmaceuticals firm Alvogen has announced exclusive commercialization agreements to distribute and market a teriparatide biosimilar in Canada, Israel and South Korea.